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Abstract
Background: Genes in inflammatory pathways play a pivotal role in the development of colorectal cancer. We
conducted a two-stage case-control study and aimed at screening the colorectal cancer-associated genetic
variations in inflammatory genes.
Methods: Twenty-three candidate variants were genotyped in 952 primary colorectal cancer cases and 875 cancer-
free controls from eastern China. Promising single nucleotide polymorphisms were further genotyped in 518 cases
and 554 controls from middle China. Expression quantitative trait loci and differential gene expression analyses
were performed for the associated gene.
Results: rs2282151 presented consistently significant associations with the risk of colorectal cancer in both
stages (odds ratio (95 % confidence interval) = 1.30 (1.16–1.46), risk allele = C, Pcombined = 8.9E-6). Gene
expression quantitative trait loci analyzes uncovered consistent cis-regulatory signals which showed that the C
allele of rs2282151 was associated with increased expression level of heat shock protein 90 alpha family class
B member 1 (HSP90AB1). Then we found that the mRNA expression levels of HSP90AB1 were significantly
higher in tumor tissues than normal tissues (fold-change = 1.83) in 28 pairs of colorectal tissue samples. The
expression difference was consistent with data from online datasets. Additionally, we observed notable peaks
of H3K27ac and H3K4me3 near the first intron of HSP90AB1 using ChIP-seq data from multiple cell lines
(including HCT116).
Conclusions: Our findings indicate that the C allele of the novel colorectal cancer-associated variant
rs2282151 is associated with increased expression levels of HSP90AB1, which is expressed higher in colorectal
tumor tissues than in normal tissues.
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Background
Colorectal cancer (CRC) is the third most common ma-
lignant neoplasm and the fourth leading cause of cancer
deaths in the world, with an estimated 1,360,000 diagno-
ses and 694,000 deaths from this disease worldwide in
2012 [1]. In China, the incidence of CRC ranked fourth
in all cancer sites with the crude rate of 23.0/100,000 in
2010, and the mortality rate for CRC was ranked fifth in
cancer-related deaths in all cancer sites with the rate of
11.1/100,000 [2].
Previous studies have shown that inflammatory pro-
cesses played an important role in the etiology of can-
cers including CRC [3–6]. It is acknowledged that
patients with inflammatory bowel disease, including
ulcerative colitis and Crohn’s disease, are at increased
risk of developing CRC [7, 8]. Evidence from previous
findings has also indicated that nonsteroidal anti-
inflammatory drugs such as aspirin could reduce the risk
of CRC [9, 10] and adenomatous polyps [11]. Genetic
factors contribute to the development of CRC through
an inflammatory process. To date, several genes in the
inflammatory pathway have been identified to be linked
to colorectal cancer, including NFKBIA, NFKBIB,
NFKBIE, IL6, STAT3, CXCL12, COX2, and PPARG etc.
[12–16]. Normally, the major transcription regulator
NFκB is inactivated in the cytoplasm by binding to its
inhibitor IκB. Phosphorylation and degradation of IκB
proteins lead to the release and nuclear localization of
NFκB proteins, which then initiate transcription of those
target genes of NFκB [17]. Dysfunction of IκB can lead
to the inhibition or constitutive activation of NFκB [18].
IκBs mainly consist of IκBα, IκBβ, and IκBγ, coded by
NFKBIA, NFKBIB, and NFKBIE, respectively. Interleukin-
6 (IL-6), an important pro-inflammatory cytokine, is
found to be associated with many types of cancers. Associ-
ations between the IL6 gene polymorphisms and CRC
have been observed by previous studies [19–22]. STAT3, a
nuclear transcription factor downstream of the IL-6 fam-
ily, has also been associated with CRC [23]. The persistent
activation of STAT3 mediates tumour-promoting inflam-
mation [16]. The expression of activated STAT3 was re-
lated to tumor invasion and poor prognosis of CRC [24].
The chemokine CXCL12 has been found to play a decisive
role in tumor progression [25], and it directs leukocyte
migration through interactions with its receptor CXCR4
[26, 27]. CXCL12/CXCR4 interactions might constitute a
promising target for specific treatment interventions [28].
In this study, we mainly focused on the polymorphism of
the candidate genes including NFKBIA, NFKBIB, NFKBIE,
IL6, STAT3, and CXCL12.
Variations in these genes may affect chronic inflamma-
tion levels, which have been linked to the risk of cancers
including CRC. Recently, genome-wide association stud-
ies (GWAS), as a powerful strategy, has been focusing
on common variants, and uncovered several point muta-
tions associated with CRC in different populations in-
cluding Asian [29–32]. However, few replicable variants
located in inflammation-related genes have been re-
ported in these studies. The small effect of the variants
on the inflammation genes and the strict false-positive
control in GWAS could be the reasonable explanations.
Many true-positive variants probably are neglected in
GWAS with P-values (in discovery stage) ranging from
0.05 to 1.0E-4, which could hardly be selected into repli-
cation stages. Evidences from a study by Zhang and col-
leagues successfully replicated six novel CRC-associated
loci which showed P-values ranging only from 0.002 to
0.03 in the discovery stage [32]. Candidate gene strategy
with a reasonable hypothesis to narrow down the candidate
single-nucleotide polymorphisms (SNPs) could be recon-
sidered after replications for the top signals in GWAS.
We conducted a two-stage case-control study between
CRC risk and genetic variants of inflammation-related
genes in Han Chinese. The promising tagSNPs from the
discovery stage were genotyped for further replication in
an independent population. Fine-mapping and func-
tional annotation were performed for replicated tagSNP
using online data sources. Differential gene expression
analysis was conducted in 28 CRC patients with tissue
samples and validated using online datasets.
Methods
Study subjects
In this study, two independent case-control studies were
performed in Han Chinese. The discovery phase con-
sisted of 952 newly diagnosed cases with primary CRC
and 875 cancer-free controls. Cases were consecutively
and systematically recruited with same diagnostic cri-
teria by trained investigators between 2006 and 2011 at
The First Affiliated Hospital, Sir Run Run Shaw Hospital
of Medical College, Zhejiang University, and Zhejiang
Taizhou Hospital (Eastern China). The pathologic diagno-
ses of CRC were evaluated by pathologists from biopsy re-
ports. Patients with familial adenomatous polyposis and
hereditary non-polyposis CRC were excluded. The healthy
controls were recruited from a population-based cross-
sectional study via a large-scale physical examination in the
medical center of the Third People’s Hospital of Xiaoshan
Zhejiang (Eastern China), from July 2010 to July 2011.
Physical examination and face-to-face survey were con-
ducted by trained investigators. Subjects were excluded
from the control group if they had 1) cancers, 2) a family
history of cancers or polyposis, or 3) serious chronic liver,
lung, heart, or kidney disorders were also excluded.
In the replication stage, considering the regional repre-
sentation, 517 CRC cases were recruited from Taihe
Hospital in Shiyan, Hubei Province (Middle China), be-
tween 2011 and 2012. 550 controls in the second stage
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were randomly selected from a community-based cancer
screening program for early detection of cancer con-
ducted in the same regions during the same time. The
diagnostic criteria and the exclusion criteria were the
same as mentioned above. Written informed consent
was obtained from all subjects, and the study protocol
was approved by the Institutional Review Board of
Zhejiang University, School of Medicine.
tagSNP selection, genotyping, and imputations
Genomic DNA was extracted from peripheral blood cells
using a TACO Nucleic Acid Automatic Extraction Sys-
tem (GeneReach Biotechnology Corp., Taiwan). All of
the TagSNPs were genotyped via the Illumina Human-
OmniExpress 760 k chip (Illumina, San Diego, CA,
USA) in the discovery stage, as described previously
[33]. SNPs with a minor allele frequency (MAF) > 0.05 in
the HapMap Han Chinese in Beijing (CHB) population
were included in the study. Only one SNP was chosen if
two or more SNPs were observed to be in high linkage
disequilibrium (r2 ≥ 0.80) in the study. A total of 23
tagSNPs near the six genes passed the quality control
procedures of the GWAS chips (including call rate >
95 %, PHardy-Weinberg Equilibrium > 0.05, etc.) and were
chosen in the first stage of the study. In the replication
phase, two promising SNPs were genotyped by the Taq-
Man allelic discrimination assay using a LightCycler®
480 Instrument (Roche, Mannheim, Germany). All the
primer and probe sequences are available upon request.
In replication stage, 10 % double-blind duplicates and
negative controls were included in each 384-well plate.
Post-quality-control GWAS data were used for imput-
ation. We imputed ungenotyped SNPs via IMPUTE2
(http://mathgen.stats.ox.ac.uk/impute/impute_v2.html)
with the worldwide haplotype reference data of 1092 in-
dividuals from the 1000 Genomes Project Phase I inte-
grated variant set (v3, released in March 2012). SNPs
with info score quality estimates < 0.8 were excluded
from the analyses. Finally, 4,642,479 SNPs were used for
fine-mapping. The genotyping call rates for these poly-
morphisms were all above 95 %.
Online data collection
Cis-expression Quantitative Trait Loci (eQTL) analyses,
i.e., the associations between genotype and mRNA ex-
pression in cis-regulation, were acquired from the
MuTHER project in multiple tissues [34] and a meta-
analysis in non-transformed peripheral blood samples
from seven studies (EGCUT, InCHIANTI, Rotterdam
Study, Fehrmann, HVH, SHIP-TREND, and DILGOM)
[35]. Evidence of differential gene expression (tumor
tissue vs normal tissue) was collected from multiple
sources including 32 pairs of samples using the Illumina
Hiseq 2000 RNA-seq platform from TCGA, 97 pairs of
samples using Affymetrix Human Genome U219 Array
from Adria Closa and colleagues [36] (GSE44076), and
103 pairs of samples using the Illumina Hiseq 2000
RNA-seq platform from the SYSCOL human CRC pro-
ject [37]. The genetic architectures surrounding repli-
cated SNPs were assessed using the Encyclopedia of
DNA Elements (ENCODE) database from the The
University of California, Santa Cruz (UCSC) genome
browser [38]. Annotated peaks of histone modification
(H3K27ac, H3K4me3) and POLR2A were called from
multiple cell lines including the CRC cell line HCT116.
Using data from the NIH Roadmap Epigenomics Map-
ping Consortium, four other colon and rectal tissue sam-
ples (including one colonic mucosa, one sigmoid colon,
and two rectal mucosa samples) were used for histone
modification annotations as supplements.
Quantitative Polymerase Chain Reaction (qPCR) analyzes
Twenty-eight pairs of tissue samples (tumor tissue and
paired adjacent normal tissue) were collected from CRC
patients during surgery at Zhejiang Taizhou Hospital
(April 2010 to April 2011). mRNA samples were ex-
tracted from these fresh tissue samples and reverse-
transcripted into cDNA for storage. qPCR was per-
formed to determine the expression levels of the target
genes using the ABI 7900HT real time PCR system (Ap-
plied Biosystems, Foster City, CA). GAPDH was used as
house-keeping gene in the current study.
Statistical analysis
The Hardy-Weinberg Equilibrium test for each SNP was
assessed by goodness-of-fit χ2 test in the control groups.
The χ2 test was used to evaluate the significant of differ-
ences in the distribution of gender. The t-test was used
to examine the differences between cases and controls in
age. In the current analyses, the minor allele of each
SNP was considered as the effect allele and the major al-
lele was considered as the reference allele. Logistic re-
gression models were used to explore the associations
between genotypes and risk of CRC in the additive
model (i.e., the genotypes were assigned “0”, “1”, “2”, ac-
cording to the number of effect alleles), and the odds ra-
tio (OR) and its 95 % confidence interval (95 % CI) were
estimated. SNPs with significant associations with CRC
in the discovery stage after false discovery rate control
by the Benjamini–Hochberg (BH) procedure were
genotyped in the replication stage. In order to control
the potential confounding effect by age, we additionally
performed analyses in subgroups stratified by age (cate-
gorized as age < 50, between 50 and 70, and age >
70 years). Meta-analyses were carried out to combine
the results from different stages. A fixed-effect model
was used when there was no indication of heterogeneity
(Cochran’s Q-statistic P > 0.05). Wilcoxon’s signed ranks
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test was carried out for the comparison of mRNA ex-
pression levels between the tumor and paired normal
tissues. Statistical analyses were performed using the
SAS for Windows software (version 9.2, SAS Institute
Inc., Cary, NC). The region around the replicated
tagSNP was plotted using LocusZoom based on the
ASN population in hg19 coordinates [39]. Histone modi-
fication annotations were visualized using the UCSC
genome browser.
Results
Basic characteristics of study subjects
Totally, 1469 cases and 1425 cancer-free controls were
recruited in this study. The characteristics of the study
subjects in the two stages are summarized in Table 1. In
both stages, no significant difference was found between
cases and controls in gender. As the cases were signifi-
cantly older compared with controls, we additionally
performed age-stratification analyses.
Associations of candidate tagSNPs with CRC
All the 23 candidate SNPs in this study population were
consistent with HWE (P > 0.05) in the controls in both
stages. The associations between candidate tagSNPs with
CRC risk is presented in Additional file 1: Table S1. Four
SNPs, including STAT3 rs1053005, CXCL12 rs1029153,
NFKBIA rs1022714, and NFKBIE rs2282151 were found
nominally associated (P < 0.05) with CRC risk via logistic
regression in an additive model adjusted for age and
gender (Additional file 1: Table S1). Two SNPs, i.e.,
rs1022714 (P = 0.003) and rs2282151 (P = 0.002), were
significantly associated with CRC after false discovery
rate correction (Table 2).
After replications, rs2282151 in NFKBIE was found to
be significantly associated with CRC risk in the same dir-
ection as in the discovery stage (Table 2). The C allele of
rs2282151 in NFKBIE was associated with a significantly
increased risk of CRC (OR = 1.24; 95 % CI: 1.08–1.42 in
the discovery stage (P = 0.002) and 1.39 (95 % CI: 1.14–
1.70) in replication stage (P = 0.001), respectively. Com-
bined statistical analysis showed that rs2282151 had a
per-allele OR of 1.30 (95 % CI: 1.16–1.46) with the com-
bined P-value of 8.9E-6. No significant heterogeneity
was observed between the discovery and replication
stages (Pheterogeneity = 0.72). Besides the additive model,
we evaluated the association of rs2282151 and CRC in
dominant and recessive models. According to the results
shown in Additional file 2: Table S2, the combined effect
sizes were closed among the additive (OR = 1.30 (1.16–
1.46)), the dominant (OR = 1.41 (1.19–1.66), and the
recessive model (OR = 1.37 (1.10–1.71)). No statistical
association was observed for rs1022714 and CRC in the
replication stage (P = 0.306).
Age-stratified analyses of rs2282151 and CRC
Because of the higher mean of ages in the case group,
we classified the samples into three groups (age < 50, be-
tween 50 and 70, and age > 70 years) and performed age-
stratified logistic regressions (controlling for gender and
age as covariates). Results showed that the effect was
consistent with the age < 50 and 50–70 years group,
while no difference was found in the > 70 years group in
discovery stage (Table 3). In combined analyses (com-
bined with discovery and replication stages), the OR and
95 % CI were 1.33 (1.09, 1.62), 1.33 (1.14, 1.55), and 1.17
(0.81, 1.68) in the < 50, 50–70 and ≥ 70 age groups, re-
spectively. The combined P-value was 6.2E-6 (combined
with three age groups).
Fine-mapping for rs2282151 and function annotations
The replicated signal of rs2282151 at 6p21.1 is located
in the 3′UTR of NFKBIE. As the regional plot shows
(Fig. 1), in this region, 12 SNPs in high linkage disequi-
librium (r2 > 0.5) with rs2282151 also displayed promis-
ing evidence of association (P = 0.008–0.027 via imputed
genotypes) in the discovery stage. Three protein-coding
Table 1 Basic characteristics of the samples in the two-stage case-control study
Discovery stage Replication stage Combined
Cases (n, %) Controls (n, %) Cases (n, %) Controls (n, %) Cases (n, %) Controls (n, %)
Gender
Female 432 (45.4) 418 (47.8) 232 (44.9) 224 (40.7) 664 (45.2) 642 (45.1)
Male 520 (54.6) 457 (52.2) 285 (55.1) 326 (59.3) 805 (54.8) 783 (54.9)
Age
Mean ± SD (years) 62.8 ± 12.3 55.3 ± 11.8 55.1 ± 10.7 45.2 ± 11.7 60.1 ± 12.3 51.4 ± 12.7
Tumor location
Colon 453 (47.9) 232 (44.9) 685 (46.6)
Rectum 471 (49.5) 223 (43.1) 694 (47.2)
Missing 28 (2.6) 62 (12.0) 90 (6.1)
Abbreviation: n number of samples
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genes (HSP90AB1, SLC35B2, and NFKBIE) and a non-
coding RNA (MIR4647) were contained in this region.
eQTL analysis was conducted using the online data-
bases. Evidence suggested that the C allele in rs2282151
was significantly associated with increased mRNA ex-
pression level of HSP90AB1 in skin tissue (MuTHER).
The effect size (beta and its 95 % CI) of the cis-regula-
tory signal was 0.09 (0.50, 0.13), P = 1.1E-5. Consistently,
the C allele of rs2282151 was associated with increased
level of HSP90AB1 in a combined analysis using expres-
sion levels from whole blood cells (P = 8.5E-4). Then we
compared the difference of mRNA expression levels of
HSP90AB1 in colorectal tumor and paired normal sam-
ples using online data sources. Tumor tissues had sig-
nificantly higher expression levels than paired normal
tissues using databases from TCGA (32 pairs of sam-
ples), SYSCOL (103 pairs of samples), and GSE44076
(97 pairs of samples). As shown in Figs. 2 and 3, the
HSP90AB1 was significantly highly expressed in tumor
tissues than normal tissues. The expression fold changes
(tumor/normal) were ranged from 2.05 to 2.19. We fur-
ther performed differential gene expression analysis in
28 paired samples from Zhejiang Taizhou hospital and
found consistent results (expression fold changes
(tumor/normal) was 1.83, P = 1.7E-3). However, the as-
sociations between the genotype of rs2282151 and the
expression of HSP90AB1 did not reach significance in
colon tissues (P > 0.05). No consistent signals were found
between rs2282151 and other genes in cis-regulatory.
Using the UCSC genome browser, we observed that
five of the SNPs tagged by rs2282151 (linkage disequilib-
rium r2 > 0.5) were located in the first intron of
HSP90AB1. As shown in Fig. 1, these five SNPs are also
located in a CpG island in this region (USCS annota-
tion). We noticed that of the five SNPs, the genotypes of
rs10948128 (flanking sequence 5′ GCG[C/G]GTC 3′)
and rs3757283 (flanking sequence 5′ GGA[A/C]GAA
3′) influence the existence of CpG sites which probably
leads to different methylation levels on these CpG sites.
Additionally, we observed remarkable histone modifica-
tion peaks (H3K27ac and H3K4me3) in eight different
cell lines including HCT116 via ChIP-seq data from the
ENCODE project (Fig. 1). We observed that the histone
modification signals (H3K27ac, H3K4me3) were consist-
ent with the signals in the HCT-116 cell line (Additional
file 3: Figure S1). Besides these SNPs, five other SNPs
tagged by rs2282151 were found to be located upstream
of HSP90AB1, while no additional evidence was found.
Discussion
We identified the tagSNP rs2282151 on chromosome
6p21.1 as a susceptibility marker for CRC by a two-stage
case-control study. This tagSNP is located in an linkage dis-
equilibrium block covering two inflammation-related genes
(NFKBIE and HSP90AB1). The C allele of rs2282151 was
associated with increased mRNA expression level of
HSP90AB1, which expressed higher in CRC tumor tissues
than paired normal tissues.
Table 2 Associations of SNPs with CRC risk in the discovery stage, replication stage and combined samples





































TC 456/401 281/251 737/652
CC 159/118 91/72 250/190
Abbreviation: Chr chromosome, OR odds ratio, 95 % CI 95%confidence interval
aLogistic regression were performed in additive model, adjusted for age and sex
*P-value after FDR control
Table 3 Age-stratified analyses of rs2282151 with CRC risk in the discovery, replication stage and combined samples
Discovery stage Replication stage Combined
Case/control OR (95 % CI) Pa Case/control OR (95 % CI) Pa Case/control OR (95 % CI) Pa
Age < 50 158/246 1.39 (1.03, 1.88) 0.029 151/390 1.28 (0.97, 1.68) 0.080 309/636 1.33 (1.09, 1.62) 0.006
50 ≤ Age < 70 520/552 1.24 (1.04, 1.48) 0.015 342/143 1.71 (1.22, 2.39) 0.002 862/695 1.33 (1.14, 1.55) 5.2E-4
Age≥ 70 274/77 1.00 (0.68, 1.47) 0.992 24/16 4.48 (1.43, 14.02) 0.010 298/93 1.17 (0.81, 1.68) 0.405
Combined 952/875 1.24 (1.07, 1.42) 0.003 517/549 1.49 (1.21, 1.84) 1.8E-4 1469/1424 1.31 (1.17, 1.47) 6.2E-6
Abbreviation: OR odds ratio, 95 % CI 95 % confidence interval
aLogistic regression were performed in additive model, adjusted for age and sex
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Fig. 1 Regional plot of the variant rs2282151 with the P-value from discovery stage in hg19 coordinate plotted by the online tool locusZoom.
Annotations on HSP90AB1 were identified using The University of California, Santa Cruz (UCSC) genome browser. The variant with the highest -log10
P value is colored purple and identified by its rs number. All other loci are represented reflecting the level of correlation with the variant. The linkage
disequilibrium is estimated using Asian samples from the 1000 Genome Project. The name and location of genes in the UCSC genome browser are
shown. A 10 kb window near the 5′ end of HSP90AB1 was annotated with CpG island, histone modification (H3K27ac, H3K4me3) and POLR2A peaks
from multiple cell lines including HCT116 from the Encyclopedia of DNA Elements project
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In this two-stage study, 1469 cases and 1425 con-
trols were recruited. All of the study subjects are Han
Chinese (an ethnic group native to East Asia), which
constitute approximately 92 % of the population of
Mainland China and about 18 % of the entire global
human population. We investigated 23 tagSNPs in six
genes in the inflammation pathway for their associa-
tions with CRC.
The additive model was used for screening CRC-
associated SNPs. Results showed that two tagSNPs
were significantly associated with CRC in discovery
stage after false discovery rate control. After the repli-
cation stage, rs2282151 maintained a consistently sig-
nificant association with increased risk of CRC. Under
different inheritance models, the allelic dose-response
trends of rs2282151 indicated that the additive model
Fig. 2 The differential gene expression (DGE) analyses revealing that the mRNA expression level of HSP90AB1 in colorectal tumor tissue was
significantly higher than paired normal tissue samples. We obtained the expression levels of colorectal tumor and paired normal tissue samples
from a The Cancer Genome Atlas (TCGA) project using RNAseq platform (32 pairs), b GSE44076 database using Affymetrix Human Genome U219
Array (97 pairs), and c Current study performed via quantitative Polymerase Chain Reaction using GAPDH as housekeeping gene (28 pairs). P-
values were calculated using two related sample Wilcoxon signed rank test. Abbreviations: N = Number of pairs
Fig. 3 Three-way associations among the variant, mRNA expression and the risk of developing colorectal cancer. Evidence for a genotype and
phenotype associations were concluded from the two-stage case-control study. b Expression quantitative trait loci (eQTL) analyses showed the
association between genotypes and mRNA expression levels. c Differential gene expression (DGE) analyses revealed the upregulated expression
levels in colorectal tumor tissues than paired normal tissues. Abbreviations: OR = odds ratio; CI = confidence interval; MuTHER = Multiple Tissue
Human Expression Resource; TCGA = The Cancer Genome Atlas; SYSCOL = Systems Biology of Colorectal Cancer; T / N = Tumor / Normal
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was suitable for the novel variant. The tagSNP
rs2282151 located in an linkage disequilibrium block
in 6p21.1. Four genes including two inflammation-
related genes NFKBIE and HSP90AB1 were located in
this linkage disequilibrium block. In order to find
clues for the causal gene, we obtained and analyzed
the results of eQTL analyses using online data from
MuTHER project. The project developed detailed gen-
omic and transcriptome data from three disease-
relevant tissues (adipose, lymphoblastoid cell lines and
skin) originating from a cohort of 856 phenotyped
twins from the TwinsUK adult registry [34]. Results
suggested C allele of rs2282151 was significantly asso-
ciated with increased expression levels of HSP90AB1
in skin tissues. This eQTL signal was replicated in
whole blood samples with a consistent direction of ef-
fect [35]. However, probably because of the limited
sample size (N = 28), the association was not repli-
cated in colon tissue samples. Beside the eQTL sig-
nals, we found significantly higher expression levels of
HSP90AB1 in CRC tumor than paired normal samples
in all three online databases. The expression differ-
ence was replicated in 28 pairs of tissue samples via
qPCR in Han Chinese.
Then we annotated the position of SNPs tagged by
rs2282151 and found five SNPs located in the first in-
tron of HSP90AB1. Using UCSC genome browser, we
found remarkable peaks of H3K27Ac and H3K4me3,
which indicated the activity of the transcription. All
these five candidate causal SNPs were located in the
peak of H3K27Ac. Notably, the polymorphisms of
rs10948128 and rs3757283 (two of the five SNPs)
were involved with the existence of CpG sites. These
CpG-site-related SNPs are called “cgSNP” or “meSNP”
and probably influence the methylation levels on the
CpG site (i.e., probably methylation QTL, mQTL)
[40–42]. Both of the two SNP-CpG pairs are located
in a CpG island overlapped with the first intron of
HSP90AB1.
Integrated with the evidence shown above, we drew a
three-way association triangle among the genotype of the
tagSNP rs2282151, the expression levels of HSP90AB1,
and the risk of CRC. As shown in Fig. 3, the C allele of
rs2282151 was associated with increased risk of CRC.
Meanwhile, the C allele of rs2282151 was associated with
increased expression level of HSP90AB1, which was
expressed higher in CRC tumor tissue than normal tissue.
The heat shock protein 90 kDa alpha (cytosolic), class B
member 1 (HSP90AB1), encodes a member of the heat
shock protein 90 (HSP90) family, which is involved in sig-
nal transduction, protein folding and degradation, and mor-
phological evolution [43–45]. HSP90AB1 is necessary for
the shuttle of client proteins between the cytoplasm and
nucleus [46, 47]. Client proteins including IκB kinase (IKK)
complex are required for HSP90 as a regulator of NFκB sig-
naling by its general involvement in IKK activation and by
its role in IKK homeostasis [48]. A study by Nagaraju
showed that the inhibition of HSP90 downregulates both
HIF-1a and NFκB leading to the inhibition of epithelial to
mesenchymal transition (EMT), motility, and invasiveness
in CRC [49]. Other studies also have shown that
HSP90AB1 was upregulated in lung cancer and melanoma
tumor [50–52]. The up-regulation in lung cancer was asso-
ciated with poor survival [51]. Since HSPs (including
HSP90) are frequently upregulated in tumor tissues and
tumor growth is supported by HSP proteins [43], inhibition
of HSPs is a promising strategy for therapy. Inhibition of
HSP90AB1 function is a potential target for CRC treat-
ment according to current studies. However, functional
studies are needed to demonstrate the role of HSP90AB1
in carcinogenesis.
However, our current study has some limitations. The
first one is the different distribution of age between the
cases and controls. In order to control the potential con-
founding effect by age, we conducted age-stratified associ-
ation analyses. The results showed the associations
between tagSNP and CRC in the < 70 years’ groups, while
no significant association was observed in the ≥ 70 years’
groups. One possible reason was the limited sample size
in this subgroup. Another explanation was the increased
attributions of environmental factors and aging in carcino-
genesis compared with genetic factors in older popula-
tions. Lack of data such as smoking, drinking behaviors
and family history of related diseases was another limita-
tion of the current study.
Conclusion
In conclusion, this study identifies a novel variant of
rs2282151, which is associated with the risk of develop-
ing CRC in Han Chinese. This association between
rs2282151 and CRC is probably mediated by the expres-
sion of the inflammatory-related gene HSP90AB1, which
is upregulated in colorectal tumor tissues. Further stud-
ies are warranted to explore the potential mechanism.
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